Skip to main content

Table 3 Changes in biochemical parameters after 16 weeks of intervention

From: Effect of oral cinnamon intervention on metabolic profile and body composition of Asian Indians with metabolic syndrome: a randomized double -blind control trial

Biochemical parameters

Cinnamon group (n = 58)

Placebo group (n = 58)

Difference between Means (95% CI)

P value a

Intention to treat analysis

FBG (mmol/L)

Baseline

5.7 ± 0.6

5.6 ± 0.5

−0.1(− 0.2, 0.1)

0.485

16 weeks

 Unadjusted

5.2 ± 0.3

5.5 ± 0.4

0.3 (0.1, 0.4)

0.001*

 Adjusted

0.3 (0.2, 0.5) b

0.001*

Per protocol analysis

FBG (mmol/L)

 

(n = 52)

(n = 51)

 

Baseline

5.7 ± 0.6

5.6 ± 0.5

−0.1 (− 0.3, 0.1)

0.528

16 weeks

 Unadjusted

5.2 ± 0.3

5.5 ± 0.4

0.3 (0.1, 0.4)

0.001*

 Adjusted

0.4 (0.2, 0.5) b

0.001*

Intention to treat analysis

HbA1c (mmol/mol)

Baseline

43.7 ± 5.4

42.4 ± 6.07

−1.3 (−3.3, 0.8)

0.250

16 weeks

 Unadjusted

39.6 ± 5.01

42.5 ± 6.8

2.9 (0.6, 5.08)

0.011*

 Adjusted

2.6 (0.4, 4.9) b

0.023*

PPG (mmol/L)

Baseline

7.4 ± 1.6

7.3 ± 1.4

−0.1 (−0.6, 0.4)

0.727

16 weeks

 Unadjusted

6.9 ± 1.4

7.4 ± 1.4

0.5 (−0.01, 1.06)

0.055*

 Adjusted

0.6 (0.1, 1.2) b

0.030*

Total cholesterol (mmol/L)

Baseline

5.23 ± 0.71

5.05 ± 0.94

−0.17 (− 0.48, 0.13)

0.259

16 weeks

 Unadjusted

4.68 ± 0.64

5.09 ± 0.92

0.41 (0.10, 0.69)

0.007*

 Adjusted

0.42 (0.12, 0.73) b

0.006*

Serum Triglycerides (mmol/L)

Baseline

1.97 ± 0.44

1.91 ± 0.48

−0.06 (−0.23, 0.10)

0.468

16 weeks

 Unadjusted

1.65 ± 0.39

1.93 ± 0.47

0.28 (0.11, 0.43)

0.001*

 Adjusted

0.20 (0.05, 0.35) b

0.010*

HDL (mmol/L)

Baseline

0.97 ± 0.15

0.96 ± 0.23

−0.003 (−0.07, 0.06)

0.922

16 weeks

 Unadjusted

1.02 ± 0.15

0.94 ± 0.22

0.08 (0.01, 0.15)

0.024*

 Adjusted

0.08 (0.005, 0.15) b

0.035*

LDL (mmol/L)

Baseline

3.46 ± 0.60

3.29 ± 0.68

- 0.16 (−0.40, 0.07)

0.178

16 weeks

 Unadjusted

3.01 ± 0.58

3.33 ± 0.66

0.32 (0.09, 0.55)

0.006*

 Adjusted

0.37 (0.13, 0.60) b

0.003*

LDL: HDL

Baseline

3.62 ± 0.79

3.55 ± 0.98

- 0.07 (−0.40, 0.25)

0.641

16 weeks

 Unadjusted

2.97 ± 0.68

3.66 ± 0.98

0.69 (0.37,0.99)

0.001*

 Adjusted

0.72 (0.40, 1.04) b

0.001*

hs- CRPc

Baseline

2.8 (2.33–3.30)

2.4 (1.98–2.86)

-

0.255

16 weeks

2.5 (2.03–2.94)

2.6 (2.21–3.09)

-

0.382

  1. CI confidence interval, FBG fasting blood glucose, HbA1c glycosylated haemoglobin, HDL-C high-density lipoprotein cholesterol, LDL–C low-density lipoprotein cholesterol, LDL: HDL low-density lipoprotein cholesterol high-density lipoprotein cholesterol ratio, PPG postprandial blood sugar
  2. a Intervention versus placebo
  3. b Difference between placebo and cinnamon groups adjusted for BMI using analysis of covariance
  4. cValues depicted as geometric mean (95%CI)
  5. *p value <0.05